Bukwang Pharm Starts Phase 2 Clinical Trial in the US for Parkinson's Disease Dyskinesia Treatment
[Asia Economy Reporter Chunhee Lee] Bukwang Pharmaceutical announced on the 29th that dosing has begun for the Phase 2 clinical trial of 'JM-010,' a treatment for Parkinson's disease dyskinesia, in the United States.
JM-010 is a new drug candidate developed by Conterapha, a Danish biotech venture and a subsidiary of Bukwang Pharmaceutical. It is expected to treat dyskinesia, which is known to occur with a 90% probability after more than 10 years of long-term use of 'Levodopa,' the drug primarily used to treat Parkinson's disease.
Bukwang Pharmaceutical is conducting clinical trials aiming for JM-010's approval in the United States, and Conterapha also initiated clinical trials last year in four European countries.
Bukwang Pharmaceutical stated, "With the dosing of the first patient this time as a milestone, we will register more patients to accelerate the clinical trial process and make every effort to soon provide LID as an essential treatment for Parkinson's disease patients."
Hot Picks Today
Taking Annual Leave and Adding "Strike" to Profiles, "It Feels Like Samsung Has Collapsed"... Unsettled Internal Atmosphere
- There Is a Distinct Age When Physical Abilities Decline Rapidly... From What Age Do Strength and Endurance Drop?
- "One Comment Could Lead to a Report": 86% of Elementary Teachers Feel Anxious; Half Consider Resignation or Career Change
- "After Vowing to Become No. 1 Globally, Sudden Policy Brake Puts Companies’ Massive Investments at Risk"
- On Teacher's Day, a Student's Gifted Cake Had to Be Cut into 32 Pieces... Why?
Bukwang Pharmaceutical aims to secure interim analysis results of JM-010 in 2022 and complete the clinical trial in 2023.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
